Elecsys CEA Assay 4491777160Recalls & reported problems
Roche Diagnostics GmbH · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 04015630938919), received between Dec 19, 2022 and May 5, 2023 — classified as 2 malfunctions.
The most frequently reported specific device problem is “Low Test Results” (2 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Low Test Results2
Patient problems
- No Clinical Signs, Symptoms or Conditions2
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
MalfunctionMay 5, 2023Low Test Results; Low Test Results
THE INITIAL REPORTER RECEIVED QUESTIONABLE ELECSYS CEA ASSAY, AND SEVERAL OTHER ASSAY RESULTS FROM AN UNSPECIFIED NUMBER OF PATIENT SAMPLES TESTED ON THE COBAS 6000 E601 (UL) V, WITH SERIAL NUMBER (B)(4). THE REPORTER STATED, THAT THE QC WAS OUT OF RANGE AND MULTIPLE PATIENT RESULTS WERE FLAGGED. THE REPORTER THEN RAN AN ASSAY PROFILE OF THE EVENING SHIFT AND NOTED, THAT THE QC FOR CEA WAS OUT OF RANGE TWICE. THE PROCELL AND CLEANCELL WERE THEN REPLACED. THE QC WAS RERUN WITH ACCEPTABLE RESULTS. THE REPORTER PULLED AN INTERFACE REPORT AND NOTICED SEVERAL LOW RESULTS ON MULTIPLE ASSAYS. THE REPORTER WAS ABLE TO PROVIDE TWO EXAMPLES OF QUESTIONABLE RESULTS. THE INITIAL RESULTS WERE REPORTED OUTSIDE OF THE LABORATORY. SAMPLE 1: ON (B)(6) 2023, THE INITIAL RESULT USING AN ALIQUOTED SAMPLE WAS 63.46 NG/ML. ON (B)(6) 2023, THE REPEAT RESULT USING THE PRIMARY TUBE (AFTER SERVICE) WAS 118.9 NG/ML. SAMPLE 2: THE INITIAL RESULT WAS 0.5 NG/ML. THE REPEAT RESULT WAS 5.66 NG/ML. THE REPEAT RESULTS WERE DEEMED CORRECT.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 16877246 ↗MalfunctionDec 19, 2022Low Test Results; Low Test Results
THERE WAS AN ALLEGATION OF A QUESTIONABLE CEA ELECSYS RESULT FROM COBAS 6000 E601 MODULE SERIAL NUMBER (B)(4). THE INITIAL RESULT WAS 0.97 NG/ML AND WAS REPORTED OUTSIDE OF THE LABORATORY. THE QC PERFORMED AFTERWARD WAS NOT ACCEPTABLE. THE CUSTOMER RECALIBRATED THE ASSAY AND RAN QC WHICH WAS ACCEPTABLE. THE CUSTOMER THEN REPEATED THE SAMPLE. THE REPEAT RESULT WAS 1.54 NG/ML AND WAS DEEMED CORRECT.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 16004402 ↗
Other SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN devices
- ADVIA Centaur® CEA 10309977Siemens Healthcare Diagnostics Inc. · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN14 reports
- ARCHITECT 07K68-27Abbott Ireland Diagnostics · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN13 reports
- Elecsys CEA 07027079190Roche Diagnostics GmbH · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN13 reports
- Atellica IM CEA 10995523Siemens Healthcare Diagnostics Inc. · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN11 reports
- ADVIA Centaur® CEA 10309978Siemens Healthcare Diagnostics Inc. · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN10 reports
- IMMULITE® 2000 Systems CEA 10380995Siemens Healthcare Diagnostics Products Ltd · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN9 reports
- Elecsys Anti-CCP 07251670190Roche Diagnostics GmbH · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN8 reports
- ARCHITECT 07K68-35Abbott Ireland Diagnostics · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN8 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page